Meritz Securities
VC Fund
Meritz Securities is a VC fund focused on Medical and Biotechnology. Securities, Investment, Finance, Trading company
- Total investments:
- 12
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Meritz Securities invests in
Stages Meritz Securities invests in
Countries Meritz Securities invests in
Round sizes
Round size
- Series A
- $4.7M–$8.2M
- Series B
- $16M–$22M
- Series C
- $18M–$45M
Investment Focus
Industry
- Medical 5 (42%)
- Biotechnology 4 (33%)
- Pharmaceutical 4 (33%)
- Health Care 3 (25%)
- Manufacturing 2 (17%)
Stage
- Series C 4 (33%)
- Series A 3 (25%)
- Series B 3 (25%)
- Post-IPO Equity 1 (8%)
- Venture - Series Unknown 1 (8%)
Country
- South Korea 10 (83%)
- China 1 (8%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Dime Bio
|
Dime Bio is a drug development company for novel dementia treatments. | $8.2M / Series A / Mar 26, 2025 | |
LDCarbon Co.
|
LD Carbon manufactures recycled resource materials designed to reduce carbon dioxide emissions. The company's eco-friendly material is manufactured by refining, processing, and commercializing combustion residues from combustion residues gas, oil, and steel that are generated through pyrolysis after crushing waste tires, enabling clients torecycle resource materials that reduce emissions, use crude oil resources, and solve environmental problems caused by waste tires for a sustainable future. | $29M / Series C / Jun 18, 2024 | |
Lanvin Group
|
Lanvin group is a fashion industry that oversees the labels lanvin, caruso, wolford, sergio rossi, and st. John knits. It is offering this assistance along with in-depth information about and connection to the fashion markets. | $130M / Post-IPO Equity / Dec 14, 2022 | |
Fuel Cell Millennium Technologies
|
Fuel Cell Millennium Technologies designs and manufactures hydrogen fuel cells and hydrogen field parts. | $4.7M / Series A / Jul 05, 2022 | |
UPPTHERA
|
UPPTHERA is a pharmaceutical company that specializes in drug development using targeted protein degradation technology. | $21.9M / Series B / May 18, 2022 | |
MetaFines
|
MetaFines is a biopharma firm that creates anticancer medications with the goal of preventing the spread of cancer. By extending and reconfiguring the indications of off-label medications for terminal tumors, the company creates minimal anticancer pharmaceuticals. It also provides subcutaneous injections and therapies, allowing patients to fightcancer and enhance their standard of living with cancer metabolism.The company develops ow-toxic medicines for metabolic cancer. This low-toxic metabolic anti-cancer agent is distinguished by being created so that metabolic anti-cancer agents that limit cell growth but operate via various pathways can work in concert with one another. | $15.7M / Series B / Apr 28, 2022 | |
Immuneoncia Therapeutics
|
ImmuneOncia is an immuno-oncology-centric biopharmaceutical company. Established in 2016 as a joint venture company between Yuhan (51%) and Sorrento (49%), ImmuneOncia will leverage both companies’ expertise in drug development and antibody engineering. Our mission is to bring safe, effective, and novel immunotherapies to oncology patientsworld-wide. ImmuneOncia’s portfolio includes diverse immune checkpoint antibodies; the lead antibody IMC-001 is in Phase 1 clinical trial. Yuhan Corporation is a South Korea-based healthcare company founded in 1926. The company has positioned itself as one of the top pharmaceutical companies in terms of market cap and sales revenue in Korea. The core business consists of primary & specialty care, dietary supplements, household & animal care, and contract manufacturing of active pharmaceutical ingredients. It has a number of subsidiaries and a global presence in the form of joint ventures with Janssen (Belgium), the Clorox Company (USA), and Kimberly-Clark Corporation (USA). Yuhan (000100:KS) is a publicly-listed company traded on the Korea Stock Exchange. | $20.6M / Venture - Series Unknown / Jan 17, 2022 | |
HUINNO
|
HUINNO, founded in 2014, is a 500 Startups and venture-backed digital healthcare company with offices in Boston, New York, and Seoul. They are focusing on changing the way clinicians and patients manage chronic cardiac diseases using their proprietary breakthrough technologies in wearable devices and AI-based analytics cloud.HUINNO'sclinically-tested platform is capable of continuously measuring a variety of vital health data in real-time with clinical-grade accuracy. --By combining wrist and chest wearables with artificial intelligence, HUINNO provides superior real-time cardiac biometrics including ECG, Blood Pressure, Heart Rate, SpO2. Delivering healthcare providers with an effective remote patient monitoring solution that drastically improves chronic cardiac disease prevention while lowering readmission rate compared to the existing standard of care. HUINNO's app and cloud-based eco-system also allow consumers to access longitudinal trend analysis of blood pressure, medication compliance, and nutritional / exercise habits as well as coaching and medication titration from HUINNO's clinical experts. | $36.6M / Series C / Dec 28, 2021 | |
Medical IP
|
Medical IP provides medical institution services for imaging analysis and 3D medical printing. | $17.9M / Series C / May 06, 2021 | |
Gridwiz
|
Gridwiz is an energy company that provides efficient, economic, safe and sustainable energy services for energy users. | $45.4M / Series C / Feb 15, 2021 | |
| See all 12 investments → | |||
Co-Investors
Meritz Securities
11 deals together
Daishin Securities
2 deals together
Hanyang Securities
2 deals together
IBK Capital
2 deals together
NH Investment & Securities
2 deals together
Time Folio Asset Management
2 deals together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Featured in Investor Lists
Recommended lists
FAQ
What does Meritz Securities invest in?
Meritz Securities invests primarily in Medical, Biotechnology and Pharmaceutical startups, most often at Series C and Series A stage. Most of the 12 investments tracked by Shizune back companies in South Korea. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Meritz Securities's check size?
Meritz Securities typically joins rounds of $4.7M–$8.2M at Series A, $16M–$22M at Series B and $18M–$45M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Meritz Securities participates in.
When did Meritz Securities last invest?
The most recent investment recorded for Meritz Securities closed in Mar 2025. Shizune tracks 12 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
